Cargando…

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC

Constantly stimulated by the tumor microenvironment (TME), programmed death 1 (PD-1) is elevated, and it interacts with PD ligand 1 (PD-L1), rendering chimeric antigen receptor (CAR)-T cells dysfunctional. Hence, CAR-T cells immune to PD-1-induced immunosuppression were constructed to improve the fu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Dezhi, Qin, Jie, Zhou, Tao, Li, Yaqin, Cheng, Xianyi, Chen, Zaizhong, Chen, Junhui, Zheng, Wei V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019756/ https://www.ncbi.nlm.nih.gov/pubmed/36896779 http://dx.doi.org/10.3892/ijo.2023.5501

Ejemplares similares

Anti-aging effect of β-carotene through regulating the KAT7-P15 signaling axis, inflammation and oxidative stress process
por: Zheng, Wei V., et al.
Publicado: (2022)

Uridine alleviates carbon tetrachloride‐induced liver fibrosis by regulating the activity of liver‐related cells
por: Zheng, Wei V., et al.
Publicado: (2021)

microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3
por: Li, Yaqin, et al.
Publicado: (2022)

LINC02362 attenuates hepatocellular carcinoma progression through the miR-516b-5p/SOSC2 axis
por: Li, Dezhi, et al.
Publicado: (2022)

Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager
por: Bi, Yanyu, et al.
Publicado: (2017)

Glucosamine-6-Phosphate Isomerase 1 Promotes Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma
por: Li, Dezhi, et al.
Publicado: (2020)

Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
por: Sun, Ming, et al.
Publicado: (2023)

Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma
por: Meng, Min, et al.
Publicado: (2021)

Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma
por: Jiang, Wei, et al.
Publicado: (2021)

GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab
por: Kato, Daiki, et al.
Publicado: (2020)

Clinical values of AFP, GPC3 mRNA in peripheral blood for prediction of hepatocellular carcinoma recurrence following OLT: AFP, GPC3 mRNA for prediction of HCC
por: Wang, Yuliang, et al.
Publicado: (2011)

Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma
por: Jiang, Zhiwu, et al.
Publicado: (2017)

PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response
por: Zurko, Joanna, et al.
Publicado: (2021)

Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
por: Borrok, M. Jack, et al.
Publicado: (2022)

Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy
por: Chen, Xianhui, et al.
Publicado: (2021)

Targeting GPC3(high) cancer-associated fibroblasts sensitizing the PD-1 blockage therapy in gastric cancer
por: Li, Dinuo, et al.
Publicado: (2023)

Development of anti-GPC-1 (glypican-1)-CAR-T cells for adoptive T cell immunotherapies for squamous cell carcinoma
por: Yaguchi, Tomonori, et al.
Publicado: (2015)

IMMU-16. TARGETING GLYPICAN 2 (GPC2) ON PEDIATRIC MALIGNANT BRAIN TUMORS WITH MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2021)

ENGINEERING T CELLS TARGETING GPC2 FOR TREATING NEUROBLASTOMA
por: Quan, Alex, et al.
Publicado: (2023)

Objective to identify and verify the regulatory mechanism of DTNBP1 as a prognostic marker for hepatocellular carcinoma
por: Cheng, Xianyi, et al.
Publicado: (2022)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
por: Thakur, Archana, et al.
Publicado: (2021)

The race is on: bispecifics vs CAR T cells in B-cell lymphoma
por: Gurumurthi, Ashwath, et al.
Publicado: (2023)

Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy
por: Shi, Yaoping, et al.
Publicado: (2023)

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
por: Xia, Baijin, et al.
Publicado: (2023)

GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer
por: Chen, Guoming, et al.
Publicado: (2022)

The Feasibility of TACE Combined with TKIs Plus PD-1 Antibody for Advanced HCC
por: Sun, Tao, et al.
Publicado: (2023)

Elevated GPC3 level promotes cell proliferation in liver cancer
por: Wang, Shanshan, et al.
Publicado: (2018)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

GPC6 Promotes Cell Proliferation, Migration, and Invasion in Nasopharyngeal Carcinoma
por: Fan, Chunmei, et al.
Publicado: (2019)

The novel lncRNA GPC5-AS1 stabilizes GPC5 mRNA by competitively binding with miR-93/106a to suppress gastric cancer cell proliferation
por: Bo, Guo, et al.
Publicado: (2022)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
por: Tang, Yuanyan, et al.
Publicado: (2022)

Low glucose metabolism in hepatocellular carcinoma with GPC3 expression
por: Li, You-Cai, et al.
Publicado: (2018)

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
por: Sun, Xuqi, et al.
Publicado: (2021)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013)

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021)

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
por: Jiang, Haiping, et al.
Publicado: (2021)

GPC-3 in hepatocellular carcinoma: current perspectives
por: Wu, Yongle, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n98blptnpg9q94kha5l897elgi